310 related articles for article (PubMed ID: 26703467)
1. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
Imoto N; Hayakawa F; Kurahashi S; Morishita T; Kojima Y; Yasuda T; Sugimoto K; Tsuzuki S; Naoe T; Kiyoi H
J Biol Chem; 2016 Feb; 291(9):4723-31. PubMed ID: 26703467
[TBL] [Abstract][Full Text] [Related]
2. The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia.
Qiu JJ; Chu H; Lu X; Jiang X; Dong S
Oncogene; 2011 Feb; 30(8):967-77. PubMed ID: 20972455
[TBL] [Abstract][Full Text] [Related]
3. Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia.
Nebral K; König M; Harder L; Siebert R; Haas OA; Strehl S
Br J Haematol; 2007 Oct; 139(2):269-74. PubMed ID: 17897302
[TBL] [Abstract][Full Text] [Related]
4. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML.
Kurahashi S; Hayakawa F; Miyata Y; Yasuda T; Minami Y; Tsuzuki S; Abe A; Naoe T
Oncogene; 2011 Apr; 30(15):1822-30. PubMed ID: 21217775
[TBL] [Abstract][Full Text] [Related]
5. PAX5 fusion genes in acute lymphoblastic leukemia: A literature review.
Fouad FM; Eid JI
Medicine (Baltimore); 2023 May; 102(20):e33836. PubMed ID: 37335685
[TBL] [Abstract][Full Text] [Related]
6. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.
Jamrog L; Chemin G; Fregona V; Coster L; Pasquet M; Oudinet C; Rouquié N; Prade N; Lagarde S; Cresson C; Hébrard S; Nguyen Huu NS; Bousquet M; Quelen C; Brousset P; Mancini SJC; Delabesse E; Khamlichi AA; Gerby B; Broccardo C
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10357-10362. PubMed ID: 30257940
[No Abstract] [Full Text] [Related]
7. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
[TBL] [Abstract][Full Text] [Related]
8. Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia.
Liu GJ; Cimmino L; Jude JG; Hu Y; Witkowski MT; McKenzie MD; Kartal-Kaess M; Best SA; Tuohey L; Liao Y; Shi W; Mullighan CG; Farrar MA; Nutt SL; Smyth GK; Zuber J; Dickins RA
Genes Dev; 2014 Jun; 28(12):1337-50. PubMed ID: 24939936
[TBL] [Abstract][Full Text] [Related]
9. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
[TBL] [Abstract][Full Text] [Related]
10. PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia.
Dang J; Wei L; de Ridder J; Su X; Rust AG; Roberts KG; Payne-Turner D; Cheng J; Ma J; Qu C; Wu G; Song G; Huether RG; Schulman B; Janke L; Zhang J; Downing JR; van der Weyden L; Adams DJ; Mullighan CG
Blood; 2015 Jun; 125(23):3609-17. PubMed ID: 25855603
[TBL] [Abstract][Full Text] [Related]
11. Biphenotypic B-lymphoid/myeloid cells expressing low levels of Pax5: potential targets of BAL development.
Simmons S; Knoll M; Drewell C; Wolf I; Mollenkopf HJ; Bouquet C; Melchers F
Blood; 2012 Nov; 120(18):3688-98. PubMed ID: 22927250
[TBL] [Abstract][Full Text] [Related]
12. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
[TBL] [Abstract][Full Text] [Related]
13. Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia.
Duque-Afonso J; Feng J; Scherer F; Lin CH; Wong SH; Wang Z; Iwasaki M; Cleary ML
J Clin Invest; 2015 Sep; 125(9):3667-80. PubMed ID: 26301816
[TBL] [Abstract][Full Text] [Related]
14. Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein.
Carbone R; Botrugno OA; Ronzoni S; Insinga A; Di Croce L; Pelicci PG; Minucci S
Mol Cell Biol; 2006 Feb; 26(4):1288-96. PubMed ID: 16449642
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein.
Vallian S; Gäken JA; Gingold EB; Kouzarides T; Chang KS; Farzaneh F
Oncogene; 1998 Jun; 16(22):2843-53. PubMed ID: 9671405
[TBL] [Abstract][Full Text] [Related]
16. PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.
Kuo HY; Huang YS; Tseng CH; Chen YC; Chang YW; Shih HM; Wu CW
Cell Cycle; 2014; 13(19):3132-42. PubMed ID: 25486572
[TBL] [Abstract][Full Text] [Related]
17. New insights into the cytoplasmic function of PML.
Salomoni P; Bellodi C
Histol Histopathol; 2007 Aug; 22(8):937-46. PubMed ID: 17503350
[TBL] [Abstract][Full Text] [Related]
18. The role of PML in tumor suppression.
Salomoni P; Pandolfi PP
Cell; 2002 Jan; 108(2):165-70. PubMed ID: 11832207
[TBL] [Abstract][Full Text] [Related]
19. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.
Nakayama J; Yamamoto M; Hayashi K; Satoh H; Bundo K; Kubo M; Goitsuka R; Farrar MA; Kitamura D
Blood; 2009 Feb; 113(7):1483-92. PubMed ID: 19047679
[TBL] [Abstract][Full Text] [Related]
20. PML-associated repressor of transcription (PAROT), a novel KRAB-zinc finger repressor, is regulated through association with PML nuclear bodies.
Fleischer S; Wiemann S; Will H; Hofmann TG
Exp Cell Res; 2006 Apr; 312(6):901-12. PubMed ID: 16412420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]